Archiv der Pharmazie最新文献

{"title":"First UV-Based Strategies Integrating Whiteness, Greenness, and Blueness Appraisals for Estimating Meloxicam and Tramadol Concurrently in Their Veterinary Mixture","authors":"Ahmed R. Mohamed,&nbsp;Eman Darweish,&nbsp;Sabry M. Attia,&nbsp;Tanveer Singh,&nbsp;Youstina M. Metias","doi":"10.1002/ardp.70323","DOIUrl":"10.1002/ardp.70323","url":null,"abstract":"<div>\u0000 \u0000 <p>Multimodal pain therapy, which combines drugs from different classes targeting distinct pain pathways, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), provides enhanced pain control in veterinary practice compared with single-agent therapy. Meloxicam (MXC), an NSAID, is frequently formulated with tramadol hydrochloride (TDH), a widely used opioid analgesic, for synergistic pain management. A comprehensive survey of the available literature revealed that no analytical method has yet been reported for the concurrent determination of meloxicam and tramadol. Therefore, this work introduces two facile and eco-friendly UV spectrophotometric methodologies for the simultaneous assay of meloxicam and tramadol in their pure forms and veterinary dosage forms. Due to the significant spectral overlap between meloxicam and tramadol, direct concurrent analysis is challenging. To resolve this spectral interference, Fourier deconvolution (FDC) and dual-wavelength (DWL) methods were developed, providing linear ranges of 2–25 µg/mL for meloxicam and 10–170 µg/mL for tramadol with satisfactory sensitivity. The proposed methods were validated according to ICH guidelines and statistically compared with the reported methods for the individual drugs using appropriate statistical tests. Furthermore, their environmental sustainability was comprehensively assessed using the AGREEprep metric, complemented by whiteness and practicality evaluations based on the RGB12 algorithm and the BAGI tool. The results demonstrate that the proposed UV methods are sustainable, sensitive, specific, and suitable for the routine simultaneous analysis of meloxicam and tramadol in veterinary dosage forms.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benzophenone Derivatives as a New Class of Anti-Infectives Against Acanthamoeba spp","authors":"Tomas Rimkus,&nbsp;Hannes Geisler,&nbsp;Taha B. El-Jourani,&nbsp;Aurélien F. A. Moumbock,&nbsp;Matthias Schiedel,&nbsp;Stephan Reichl","doi":"10.1002/ardp.70321","DOIUrl":"https://doi.org/10.1002/ardp.70321","url":null,"abstract":"<p>The rare but sight-threatening ocular disease <i>Acanthamoeba</i> keratitis represents a therapeutic challenge due to its causative agents, <i>Acanthamoeba spp</i>., being able to penetrate the corneal epithelium and persist in the corneal stroma as dormant and highly resistant cysts. To combat the scarcity and limitations of current treatment options, we developed a new class of anti-infective agents against <i>Acanthamoeba spp</i>. based on Ro 48-8071 (<b>3</b>), a known inhibitor of the human oxidosqualene cyclase (hOSC). The compound design was guided by docking studies using a homology model of the cycloartenol synthase (CAS), which is the homolog of hOSC found in <i>Acanthamoeba spp</i>. and essential for the parasite's steroid biosynthesis. Among the synthesized Ro 48-8071 analogues, MSHG19 (<b>4f</b>) evoked the most potent activity against <i>Acanthamoeba hatchetti</i> leading to total eradication of trophozoites and cysts at single-digit micromolar concentrations, whereas having no effects within this concentration range on the viability of human corneal epithelial cells. With our initial set of synthesized compounds, we established a first structure–activity relationship model, which nicely aligns with the predicted binding mode of <b>4f</b> to CAS. Overall, the presented findings highlight the potential of benzophenones as a new class of anti-infectives for the treatment of <i>Acanthamoeba</i> keratitis.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70321","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Developments and Structure–Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery","authors":"Xin-Ke Guo,&nbsp;Kadalipura P. Rakesh,&nbsp;Sahana Raju,&nbsp;Kothanahally S. Sharath Kumar,&nbsp;Hua-Li Qin","doi":"10.1002/ardp.70322","DOIUrl":"https://doi.org/10.1002/ardp.70322","url":null,"abstract":"<div>\u0000 \u0000 <p>Incorporating current structural and biochemical discoveries, this paper examines how B-RAF inhibitors control B-RAF, including their clinical efficacy, side effects, and important medicinal chemistry characteristics. It investigates the molecular insights that may direct the creation of more potent RAF inhibitors that can target different oncogenic B-RAF conformations. We have discussed the advantages and disadvantages of structurally varied next-generation RAF inhibitors that are presently undergoing preclinical and clinical trials. A few of these drug candidates have started clinical trials with promising outcomes. This review also covers the structure–activity relationship of promising bioactive B-RAF compounds, highlights advancements in the discovery and development of B-RAF inhibitors, and attempts to assist future drug discovery initiatives.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural Modifications of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): New Horizons in Antimicrobial Drug Discovery","authors":"Ebru Koçak Aslan,&nbsp;Ayşe Karagüzel,&nbsp;Miyase Gözde Gündüz","doi":"10.1002/ardp.70319","DOIUrl":"https://doi.org/10.1002/ardp.70319","url":null,"abstract":"<p>Nonsteroidal anti-inflammatory drugs (NSAIDs) are traditionally recognized for their analgesic and anti-inflammatory effects, mediated by inhibition of cyclooxygenase (COX) enzymes. However, many NSAIDs have been shown to possess intrinsic antimicrobial effects beyond their classical properties. This unexpected activity, together with the rise of antimicrobial resistance, has positioned NSAIDs and their derivatives as promising scaffolds for antimicrobial drug discovery. Additionally, their well-established pharmacological profiles and chemical structures suitable for modification make NSAIDs attractive starting points for developing novel antimicrobial agents. This review, for the first time, focuses exclusively on molecular modifications directly applied to NSAIDs to develop new antimicrobial agents that combat the growing problem of antimicrobial resistance and overcome the limitations of current clinical therapies. These modifications include conjugating commercial NSAIDs with heterocyclic compounds (such as triazole, thiazolidinone, and benzimidazole), functional groups (including hydrazide-hydrazone, Schiff base, hydroxamic acid, amide, and thiosemicarbazide), and other drug molecules (fluconazole, sulfamethoxazole, isoniazid, etc.), resulting in the development of novel antimicrobial agents and an enhanced understanding of their structure–activity relationships. By integrating chemical and biological findings, this review highlights the potential of modifying NSAIDs as a viable strategy to expand the current antimicrobial arsenal and address the growing challenge of antimicrobial resistance.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70319","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cellular and Molecular Mechanisms of Berberine in Cancer Therapy: Recent Advances","authors":"Kang He,&nbsp;Bing-Rui Lu,&nbsp;Xu-Ying Shi,&nbsp;Run-Long Sui,&nbsp;Zhi-Gang Sun","doi":"10.1002/ardp.70313","DOIUrl":"10.1002/ardp.70313","url":null,"abstract":"<div>\u0000 \u0000 <p>In recent years, the role of traditional Chinese medicine (TCM) in comprehensive cancer treatment has become increasingly prominent, gradually emerging as an important adjunctive modality alongside conventional therapies such as surgery, chemotherapy, and radiotherapy, and attracting widespread attention. Berberine, an isoquinoline alkaloid extracted from natural plants such as <i>Coptis chinensis</i>, possesses broad-spectrum and potent pharmacological activities. A large body of evidence has demonstrated that berberine exerts definite antitumor effects in various cancer models, with its mechanisms of action spanning multiple dimensions, including cell-cycle arrest, induction of cell death, modulation of the tumor microenvironment (TME), inhibition of invasion and metastasis, and intervention in angiogenesis. Based on the latest research progress worldwide, this review focuses on key oncogenic signaling pathways and immune regulatory mechanisms to systematically elucidate the cellular and molecular mechanisms underlying the antitumor activity of berberine, and further discusses its clinical application potential and the challenges ahead. Although the clinical translation of berberine remains constrained by bottlenecks such as formulation optimization and bioavailability enhancement, its broad prospects in the field of cancer prevention and treatment establish it as a highly valuable TCM-derived antitumor candidate for further development.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venom-Derived Peptides in Breast Cancer: Pharmacological Mechanisms and Medicinal Chemistry-Guided Translational Development","authors":"Radwa A. Amen,&nbsp;Alyaa Farid,&nbsp;Mohamed A. Abdel-Rahman,&nbsp;Ahmed A. El-Sherif,&nbsp;Yaser M. Hassan,&nbsp;Nadia R. Shehata,&nbsp;Rana H. Ahmed,&nbsp;Wael M. El-Sayed","doi":"10.1002/ardp.70320","DOIUrl":"10.1002/ardp.70320","url":null,"abstract":"<div>\u0000 \u0000 <p>Breast cancer remains the most prevalent malignancy among women worldwide and continues to present major therapeutic challenges, including drug resistance, systemic toxicity, and limited long-term efficacy despite advances in multimodal treatment strategies. These limitations have intensified interest in venom-derived peptides as structurally diverse bioactive scaffolds with anticancer potential. This review evaluates venom-derived peptides in breast cancer from a medicinal chemistry and translational drug development perspective. A structured narrative synthesis of the literature was conducted, covering preclinical and early translational studies of peptides derived from snakes, spiders, scorpions, and bees, with emphasis on structure–function relationships, mechanisms of action, and optimization strategies. Unlike previous reviews that primarily focus on individual venom sources, this work integrates mechanistic pharmacology with peptide engineering and translational constraints to provide a unified drug-development framework across breast cancer subtypes. Venom-derived peptides exert anticancer effects through ion channel modulation, apoptosis induction, cell cycle arrest, angiogenesis inhibition, membrane disruption, and immune modulation, with reported selectivity toward malignant cells in triple-negative, HER2-positive, and hormone receptor-positive models. Despite encouraging preclinical evidence, clinical translation is limited by instability, immunogenicity, poor pharmacokinetics, delivery barriers, and manufacturing challenges. Emerging advances in peptide engineering, nanodelivery systems, and artificial intelligence-assisted design offer promising strategies to improve pharmacological performance and drug-like properties. Overall, this review provides a medicinal chemistry-guided framework that identifies the key steps and remaining challenges required to support the future development of venom-derived peptides as anticancer lead scaffolds for breast cancer.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olikomycin A Disrupts Gram-Positive Bacterial Membranes Through Calcium-Dependent Binding to Phosphatidylglycerol","authors":"Luisa Munz,&nbsp;Olga Makshakova,&nbsp;Sara Marchi,&nbsp;Winfried Römer,&nbsp;Andreas Bechthold","doi":"10.1002/ardp.70318","DOIUrl":"10.1002/ardp.70318","url":null,"abstract":"<p>Calcium-dependent antibiotics (CDAs) represent an important class of antimicrobial agents active against Gram-positive pathogens. Olikomycin A, produced by <i>Streptomyces ghanaensis</i> Δ<i>wblA</i>, displays potent activity against multidrug-resistant bacteria; however, its molecular mode of action remained unclear. In this study, we investigated the interaction of olikomycin A with bacterial membrane lipids. Phospholipid antagonization assays demonstrated a calcium-dependent interaction with phosphatidylglycerol (PG), a major anionic phospholipid of Gram-positive membranes. Cryo-electron microscopy and fluorescence microscopy using model membranes revealed rapid membrane disruption induced by olikomycin A, resulting in vesicle deformation and fragmentation. Compared with the clinically used lipopeptide daptomycin, olikomycin A caused markedly faster and more extensive membrane damage. Furthermore, treatment of <i>Staphylococcus aureus</i> with olikomycin A in the presence of calcium resulted in rapid cellular aggregation consistent with severe membrane perturbation. These findings indicate that olikomycin A targets bacterial membranes via calcium-dependent binding to PG and disrupts membrane integrity through a mechanism distinct from daptomycin.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70318","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148756929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis and Characterization of Tritium-Labeled Neuropeptide Y Y5 Receptor Ligands Derived From CGP71683A","authors":"Franziska Schettler,&nbsp;Pierre Koch,&nbsp;Max Keller","doi":"10.1002/ardp.70314","DOIUrl":"10.1002/ardp.70314","url":null,"abstract":"<p>Among the human neuropeptide Y (NPY) receptors, the Y₅ receptor (Y₅R) represents a potential therapeutic target for the treatment of obesity and stress-related diseases. As the Y₅R is expressed in various malignant tumors, it is also considered a potential target for cancer diagnosis and therapy. Although numerous non-peptidic Y₅R antagonists with high binding affinity have been reported, only labeled peptidic agonists are used in routine Y₅R competition binding assays, which are needed for the development and characterization of Y₅R ligands. In the present study, three radiolabeled derivatives of the high-affinity Y₅R antagonist CGP71683A (<b>1</b>) were synthesized ([³H]<b>26</b>, [³H]<b>32</b>, [³H]<b>42</b>) and studied in saturation binding assays using adherent or suspended HEC-1B-hY₅R cells or membrane preparations thereof. Their <i>K</i>_d values (1.5–13 nM) were consistent with the <i>K</i>_i values (1.3–11 nM) of the non-labeled analogs. However, all synthesized radioligands exhibited very high non-specific binding, primarily caused by binding of the radioligands to cellular membranes, which limits their use as tool compounds in radiochemical Y₅R binding assays. Nevertheless, a competition binding assay with [³H]<b>32</b> and the endogenous Y₅R agonist hNPY afforded a <i>K</i>_i that was in agreement with literature data.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70314","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking the Myb–KIX Alliance: Structure-Guided Discovery of Biaryl Hydroxy-Naphthamides as Disruptors of the c-Myb–CBP/p300 KIX Protein–Protein Interaction","authors":"Haifa E. Alfassam,&nbsp;Emadeldin M. Kamel,&nbsp;Sarah I. Othman,&nbsp;Hanan M. Alharbi,&nbsp;Hassan A. Rudayni,&nbsp;Ahmed A. Allam,&nbsp;Al Mokhtar Lamsabhi","doi":"10.1002/ardp.70317","DOIUrl":"10.1002/ardp.70317","url":null,"abstract":"<div>\u0000 \u0000 <p>The interaction between the transcription factor c-Myb and the CBP/p300 KIX domain is a critical regulatory node in hematopoietic gene expression and an attractive target in MYB-dependent leukemia. Herein, we aimed to identify new small-molecule disruptors of the c-Myb–CBP/p300 KIX protein–protein interaction using integrated in silico and experimental workflow. A focused library of 1143 biaryl hydroxy-naphthamides (naphthanilides) was subjected virtual screening filters yielding five prioritized candidates (C1–C5). Docking showed that all selected compounds occupied the c-Myb-facing groove of the KIX domain and reproduced key interfacial contacts. Subsequent 1000 ns molecular dynamics simulations revealed distinct stability and disruption profiles, with C1 and C4 showing the most favorable combination of stable groove occupancy, protein–protein interface perturbation, and ligand-binding energetics. Free-energy landscape analysis further supported these compounds as the most conformationally stable interfacial binders. Differential MM/PBSA analysis of the protein–protein interface showed that C1 produced the largest predicted weakening of the c-Myb–KIX interaction (ΔΔG_PPI = +38.81 kcal/mol), followed by C4 (+29.90), C5 (+27.78), and C3 (+25.81 kcal/mol), whereas C2 was predicted to stabilize the complex (−5.41 kcal/mol). In silico ADMET profiling indicated that the series was drug-like by Lipinski criteria but carried liabilities related to solubility, metabolism, and predicted toxicity. Experimental validation by microscale thermophoresis confirmed direct binding of the assay proteins (<i>K_d</i> = 26.72 ± 0.82 µM) and demonstrated that the naphthanilides disrupt the interaction in vitro. C1 was the most potent disruptor (IC₅₀ = 9.50 ± 0.22 µM), outperforming Naphthol AS-E phosphate (IC₅₀ = 32.84 ± 9.46 µM). These findings establish 3-hydroxy-2-naphthamides as promising scaffolds for targeting the c-Myb–CBP/p300 KIX interface.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, Synthesis, and Biological Evaluation of Biphenylsulfonyl Indole-Based Thiosemicarbazones as Potential AChE and CA I-II Inhibitors","authors":"Fatima Yaqoob,&nbsp;Nastaran Sadeghian,&nbsp;Feyzi Sinan Tokali,&nbsp;Parham Taslimi,&nbsp;Adel Qlayel Alkhedaide,&nbsp;Aiysha Althobaiti,&nbsp;Orhan Ulucay,&nbsp;Mohamed M. Ibrahim,&nbsp;Magdi E. A. Zaki,&nbsp;Sobhi M. Gomha,&nbsp;Xianliang Zhao,&nbsp;Halil Şenol,&nbsp;Muhammad Usman Janjua,&nbsp;Zahid Shafiq","doi":"10.1002/ardp.70315","DOIUrl":"10.1002/ardp.70315","url":null,"abstract":"<div>\u0000 \u0000 <p>In this study, 20 novel biphenyl-sulfonamide-indole-based thiosemicarbazone derivatives <b>(1–20)</b> were synthesized and evaluated for their inhibitory activities against AChE, hCA I, and hCA II. Among the synthesized compounds, compound <b>20</b> (4-nitrophenyl substituted) exhibited the highest inhibitory activity against all three enzymes (AChE <i>K</i>_i = 54.24 nM; hCA I <i>K</i>_i = 12.75 nM; hCA II <i>K</i>_i = 8.72 nM) and behaved as a competitive inhibitor in enzyme kinetic studies. To further explore the experimentally observed AChE inhibition, induced fit docking (IFD), MM-GBSA calculations, and molecular dynamics simulations were performed for compound <b>20</b>, suggesting a plausible binding mode within the AChE active site. In silico ADME analysis indicated generally favorable drug-like properties for the synthesized compounds. These findings identify biphenyl-sulfonamide-indole-based thiosemicarbazones as promising AChE and carbonic anhydrase inhibitors for further biological investigation.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"359 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}